Evidence mapPaperPMID 40958829Full record

ReviewFrontiers in bioengineering and biotechnology2025

Development of pathological skin models: from conventional techniques to 3D bioprinting.

Maïté Rielland, Françoise Bernerd, Marie Camman, Xuezhu Tan, Nathalie Seyler

Abstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maïté Rielland *L'Oréal Research and Innovation, Aulnay-sous-Bois, France.
Françoise Bernerd *L'Oréal Research and Innovation, Aulnay-sous-Bois, France.
Marie CammanL'Oréal Research and Innovation, Aulnay-sous-Bois, France.
Xuezhu TanL'Oréal Research and Innovation, Aulnay-sous-Bois, France.
Nathalie SeylerL'Oréal Research and Innovation, Aulnay-sous-Bois, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reconstructed human skin models were first developed in the 1970s. Since then, they have played a pivotal role in dermatological research, significantly advanced our understanding of skin biology, and brought huge insights into dermatological pathologies. Many conventional pathological skin models exist covering a wide range of diseases including melanomas, psoriasis, atopic dermatitis, genetic disorders, and wound healing conditions. However, conventional skin models remain limited by technical constraints which prevent complete replication of the spatial organization (heterogeneities, microenvironment) of skin diseases. Bioprinting has emerged as a powerful technology with the potential to overcome some of these limitations. By enabling precise control over the spatial organization of multiple cell types within a tailored extracellular matrix, bioprinting facilitates the creation of complex, three-dimensional skin models that closely mimic the architecture and function of human skin. This review initially explores the current landscape of conventional reconstructed pathological skin models. Bioprinting techniques, bioink considerations, and their roles in creating complex skin models are discussed. It then highlights the benefits of bioprinting for tissue microenvironment replication, architectural fidelity, and integration of multiple cell types in pathological skin models. In terms of healthy skin models, three-dimensional bioprinting is already revolutionizing personalized medicine, automating model production, and supporting translational research and therapeutic and cosmetic screening. It also represents a transformative approach for developing advanced pathological skin models despite the remaining technical and regulatory challenges.

Indexed as

bioengineeringbioprintinghuman skinpathological skinreconstructed skin

Identifiers

PMID40958829
PMCPMC12434336

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.